# Sage Therapeutics, Inc.

Sage Therapeutics, Inc. is a company headquartered in Cambridge, MA, United States.

## Company overview

- **Legal name:** Sage Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Cambridge, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001597553

## About

Sage Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001597553, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-02-11, it reported annual revenue of USD 41,243,000; net income of USD -400,666,000; total assets of USD 547,222,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $41.2M (USD 41,243,000)
- **Net income:** -$400.7M (USD -400,666,000)
- **Total assets:** $547.2M (USD 547,222,000)
- **Cash and equivalents:** $81.0M (USD 81,021,000)
- **Operating cash flow:** -$267.2M (USD -267,194,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $86.5M (USD 86,455,000)
- **Net income:** -$541.5M (USD -541,489,000)
- **Total assets:** $882.3M (USD 882,277,000)
- **Cash and equivalents:** $71.0M (USD 70,992,000)
- **Operating cash flow:** -$540.6M (USD -540,585,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $7.7M (USD 7,686,000)
- **Net income:** -$532.8M (USD -532,784,000)
- **Total assets:** $1.4B (USD 1,356,449,000)
- **Cash and equivalents:** $162.7M (USD 162,700,000)
- **Operating cash flow:** -$460.0M (USD -460,036,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $6.3M (USD 6,308,000)
- **Net income:** -$457.9M (USD -457,892,000)
- **Total assets:** $1.8B (USD 1,825,288,000)
- **Cash and equivalents:** $294.2M (USD 294,233,000)
- **Operating cash flow:** -$378.2M (USD -378,182,000)

## Recent SEC filings

- Form 8-K — filed 2025-07-31 — period 2025-07-30 — 8-K
- Form 10-Q — filed 2025-07-30 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-07-30 — period 2025-07-30 — 8-K
- Form 8-K — filed 2025-06-16 — period 2025-06-13 — 8-K
- Form 8-K — filed 2025-06-13 — period 2025-06-11 — 8-K
- Form 10-Q — filed 2025-04-29 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-04-29 — period 2025-04-29 — 8-K
- Form DEF 14A — filed 2025-04-24 — period 2025-04-23 — DEF 14A
- Form 8-K — filed 2025-03-04 — period 2025-03-03 — 8-K
- Form 10-K — filed 2025-02-11 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-02-11 — period 2025-02-11 — 8-K
- Form 8-K — filed 2025-01-27 — period 2025-01-27 — 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/sage-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology